Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Stock Exchange of Hong Kong  >  Beigene Ltd    6160   KYG1146Y1017

BEIGENE LTD

(6160)
  Report  
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (HKD)
Sales 2019 1 773 M
EBIT 2019 -5 817 M
Net income 2019 -6 040 M
Finance 2019 4 937 M
Yield 2019 -
Sales 2020 2 455 M
EBIT 2020 -5 254 M
Net income 2020 -5 395 M
Finance 2020 7 338 M
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales2019 29,3x
EV / Sales2020 20,2x
Capitalization 56 810 M
More Financials
Company
BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib... 
More about the company
Surperformance© ratings of Beigene Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on BEIGENE LTD
06/21BEIGENE : Announces Phase 1b Clinical Results of Zanubrutinib in Combination wit..
AQ
06/21BEIGENE : Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients ..
AQ
06/21BEIGENE : Announces Phase 1b Clinical Results of Zanubrutinib in Combination wit..
AQ
06/21BEIGENE : Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients ..
AQ
06/20BEIGENE, LTD. : Regulation FD Disclosure, Other Events, Financial Statements and..
AQ
06/20BeiGene Announces Phase 1b Clinical Results of Zanubrutinib in Combination wi..
GL
06/20BeiGene Presents Pivotal Phase 2 Clinical Results of Zanubrutinib in Patients..
GL
06/20BEIGENE : China's BeiGene extends gains on launch of new firm with US biopharma
AQ
06/20BEIGENE : Announces Updated Results from Two Ongoing Clinical Trials of Zanubrut..
AQ
06/19BeiGene Announces Updated Results from Two Ongoing Clinical Trials of Zanubru..
GL
More news
Sector news : Bio Therapeutic Drugs
06/21Regeneron, Sanofi Report Positive Topline Phase 2 Asthma Results
DJ
06/20EXELIXIS : Phase 3 Combination Study for Melanoma Didn't Meet Primary Endpoint
DJ
06/19PFIZER : Fitch Puts Pfizer on Watch Negative, Notes Leverage Increase
DJ
06/19GILEAD SCIENCES : Sets Collaboration With Nurix Therapeutics
DJ
06/18WHAT'S NEWS : Business & Finance -- WSJ
DJ
More sector news : Bio Therapeutic Drugs
Chart BEIGENE LTD
Duration : Period :
Beigene Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 105  HKD
Spread / Average Target 44%
EPS Revisions
Managers
NameTitle
John V. Oyler Chairman & Chief Executive Officer
Xiao Bin Wu President
Maggie Liu Head-Operations
Howard Liang Chief Financial & Strategy Officer
Jane E Huang Chief Medical Officer-Hematology
Sector and Competitors
1st jan.Capitalization (M$)
BEIGENE LTD7 219
GILEAD SCIENCES10.06%80 909
VERTEX PHARMACEUTICALS9.24%42 680
REGENERON PHARMACEUTICALS-16.32%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC16.69%8 523